Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer.
Adult
Aged
Aged, 80 and over
Carcinoma, Transitional Cell
/ drug therapy
Cell Line, Tumor
Doxorubicin
/ administration & dosage
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Gonadotropin-Releasing Hormone
/ genetics
Humans
Male
Middle Aged
RNA, Messenger
/ genetics
Receptors, LHRH
/ genetics
Urinary Bladder Neoplasms
/ drug therapy
LHRH receptor
RT-PCR
Western Blot
bladder cancer
immunohistochemistry
radioligand binding assay
targeted therapy
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
26 Feb 2021
26 Feb 2021
Historique:
received:
26
01
2021
revised:
18
02
2021
accepted:
23
02
2021
entrez:
3
3
2021
pubmed:
4
3
2021
medline:
7
4
2021
Statut:
epublish
Résumé
Bladder cancer (BC) is the tenth most frequently detected cancer in both sexes. Type-I luteinizing hormone-releasing hormone (LHRH) receptor (LHRH-R-I) is expressed not only in the pituitary, but also in several types of cancer disease. There are few data about LHRH-R-I expression in human BC. This study aimed to investigate the expression of LHRH and LHRH-R-I in the transitional cell carcinoma (TCC) type of human BC. RNA was extracted from 24 human bladder tumor specimens and three BC cell lines. RT-PCR was performed to detect mRNA for LHRH and LHRH-R-I. The protein of LHRH-R-I was further studied by immunohistochemistry (IHC), ligand competition assay, and Western Blot. PCR products of LHRH were found in 19 of 24 (79%) specimens and mRNA of LHRH-R-I was detected in 20 of 24 specimens (83%). Positive immunostaining for LHRH-R-I with different expression intensity was found in all samples examined, showing negative correlation with TCC grade. Radioligand binding studies also showed the presence of specific LHRH-R-I and high affinity binding of LHRH analogs. The high incidence of LHRH-R in BC suggests that it could serve as a molecular target for therapy of human BC with cytotoxic LHRH analogs or modern powerful antagonistic analogs of LHRH.
Identifiants
pubmed: 33652606
pii: molecules26051253
doi: 10.3390/molecules26051253
pmc: PMC7956722
pii:
doi:
Substances chimiques
RNA, Messenger
0
Receptors, LHRH
0
Gonadotropin-Releasing Hormone
33515-09-2
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : GINOP
ID : GINOP-2.3.2-15-2016-00043
Organisme : Higher Education Institutional Excellence Programme
ID : NKFIH-1150-6/2019
Références
J Urol. 2000 Feb;163(2):623-9
pubmed: 10647698
Oncotarget. 2012 Jul;3(7):686-99
pubmed: 22824624
Clin Cancer Res. 2005 Aug 1;11(15):5549-57
pubmed: 16061872
Prostate. 2011 Apr;71(5):445-52
pubmed: 20859992
Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):157-67
pubmed: 17237842
Nihon Hinyokika Gakkai Zasshi. 1995 Nov;86(11):1666-72
pubmed: 8551710
Theriogenology. 2007 Jan 15;67(2):353-66
pubmed: 17010418
J Oncol. 2011;2011:528353
pubmed: 21941546
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15677-82
pubmed: 9861029
Front Neuroendocrinol. 2001 Oct;22(4):248-91
pubmed: 11587553
Int J Oncol. 2009 Nov;35(5):1053-9
pubmed: 19787259
Scand J Urol Nephrol Suppl. 2008 Sep;(218):116-30
pubmed: 18815926
J Clin Endocrinol Metab. 1993 Dec;77(6):1458-64
pubmed: 8263128
Endocr Rev. 2005 Apr;26(2):283-306
pubmed: 15561800
Urol Oncol. 2013 Jan;31(1):9-16
pubmed: 20864362
Endocr Relat Cancer. 2009 Mar;16(1):123-37
pubmed: 18845648
Onco Targets Ther. 2018 Feb 22;11:933-941
pubmed: 29503568
Endocr Rev. 2004 Apr;25(2):235-75
pubmed: 15082521
Eur J Endocrinol. 1999 Jul;141(1):1-14
pubmed: 10407215
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Expert Rev Anticancer Ther. 2011 Dec;11(12):1851-62
pubmed: 22117153
Curr Drug Targets. 2016;17(5):488-94
pubmed: 26951061
J Oncol Pharm Pract. 2019 Apr;25(3):648-656
pubmed: 30304985
Endocrinology. 2002 Mar;143(3):737-43
pubmed: 11861490
Gynecol Oncol. 2010 Dec;119(3):457-61
pubmed: 20828803
Urol Int. 2008;80(4):431-8
pubmed: 18587256
Mol Cell Endocrinol. 1996 Jun 18;120(1):51-7
pubmed: 8809738
Cancer Treat Rev. 2012 Jun;38(4):311-7
pubmed: 22113129
Endocr Rev. 2003 Aug;24(4):389-427
pubmed: 12920149
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7269-73
pubmed: 8692981
Mol Cell Endocrinol. 1993 Feb;91(1-2):R1-6
pubmed: 8386108
Cancer Res. 1993 Nov 15;53(22):5439-46
pubmed: 8221683
Eur Urol Focus. 2019 May;5(3):457-466
pubmed: 29366854
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21
pubmed: 19666525
Trends Endocrinol Metab. 2004 Sep;15(7):300-10
pubmed: 15350601
Endocr Rev. 1994 Aug;15(4):462-99
pubmed: 7988482
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593